ERBB2 and amyotrophic lateral sclerosis: Intriguingly, previous studies have shown that the production of anti‐neutral glycolipid (NGL) autoantibody (which leads to the activation complement system) has been observed in experimental and human Gaucher disease (GD) and amyotrophic lateral sclerosis (ALS) transgenic mice ([1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13], see [14] for review).